ZA200202160B - Drug for treating fractures. - Google Patents
Drug for treating fractures. Download PDFInfo
- Publication number
- ZA200202160B ZA200202160B ZA200202160A ZA200202160A ZA200202160B ZA 200202160 B ZA200202160 B ZA 200202160B ZA 200202160 A ZA200202160 A ZA 200202160A ZA 200202160 A ZA200202160 A ZA 200202160A ZA 200202160 B ZA200202160 B ZA 200202160B
- Authority
- ZA
- South Africa
- Prior art keywords
- substance
- composition
- bone
- drug
- bisphosphonate
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 65
- 229940079593 drug Drugs 0.000 title claims description 57
- 210000000988 bone and bone Anatomy 0.000 claims description 168
- 229940122361 Bisphosphonate Drugs 0.000 claims description 86
- 150000004663 bisphosphonates Chemical class 0.000 claims description 82
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical group OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 43
- 229960004276 zoledronic acid Drugs 0.000 claims description 41
- 230000011164 ossification Effects 0.000 claims description 35
- 230000000638 stimulation Effects 0.000 claims description 24
- 230000001737 promoting effect Effects 0.000 claims description 14
- 230000004044 response Effects 0.000 claims description 10
- 238000001802 infusion Methods 0.000 claims description 9
- 238000001356 surgical procedure Methods 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000003111 delayed effect Effects 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 238000002604 ultrasonography Methods 0.000 claims description 3
- 239000004053 dental implant Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 35
- 239000000126 substance Substances 0.000 claims 35
- 239000002547 new drug Substances 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 63
- 229940046231 pamidronate Drugs 0.000 description 49
- 210000002303 tibia Anatomy 0.000 description 48
- 206010017076 Fracture Diseases 0.000 description 43
- 241000283973 Oryctolagus cuniculus Species 0.000 description 33
- 208000010392 Bone Fractures Diseases 0.000 description 29
- 210000003414 extremity Anatomy 0.000 description 26
- 229910052500 inorganic mineral Inorganic materials 0.000 description 25
- 239000011707 mineral Substances 0.000 description 25
- 241001465754 Metazoa Species 0.000 description 24
- 230000000694 effects Effects 0.000 description 23
- 238000004458 analytical method Methods 0.000 description 14
- 238000005259 measurement Methods 0.000 description 14
- 230000035876 healing Effects 0.000 description 13
- 210000002414 leg Anatomy 0.000 description 11
- 208000001132 Osteoporosis Diseases 0.000 description 9
- 230000008468 bone growth Effects 0.000 description 9
- 206010020649 Hyperkeratosis Diseases 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 210000000963 osteoblast Anatomy 0.000 description 8
- 238000005452 bending Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000000540 analysis of variance Methods 0.000 description 6
- 230000001582 osteoblastic effect Effects 0.000 description 6
- 210000002997 osteoclast Anatomy 0.000 description 6
- 230000008092 positive effect Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000001054 cortical effect Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 210000003141 lower extremity Anatomy 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 210000004872 soft tissue Anatomy 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 208000008924 Femoral Fractures Diseases 0.000 description 4
- 208000034970 Heterotopic Ossification Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000007941 heterotopic ossification Effects 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 208000020431 spinal cord injury Diseases 0.000 description 4
- 238000012353 t test Methods 0.000 description 4
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 208000006386 Bone Resorption Diseases 0.000 description 3
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 3
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 3
- 102000003982 Parathyroid hormone Human genes 0.000 description 3
- 108090000445 Parathyroid hormone Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 229940062527 alendronate Drugs 0.000 description 3
- 238000001949 anaesthesia Methods 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- -1 bisphosphonate etidronate Chemical class 0.000 description 3
- 230000024279 bone resorption Effects 0.000 description 3
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 3
- 229960001736 buprenorphine Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 238000013401 experimental design Methods 0.000 description 3
- 230000009036 growth inhibition Effects 0.000 description 3
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 3
- 229960003132 halothane Drugs 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- LWRDQHOZTAOILO-UHFFFAOYSA-N incadronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 description 3
- 229950006971 incadronic acid Drugs 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 229960003299 ketamine Drugs 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000000199 parathyroid hormone Substances 0.000 description 3
- 229960001319 parathyroid hormone Drugs 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000009101 premedication Methods 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 238000011555 rabbit model Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 3
- 229960001600 xylazine Drugs 0.000 description 3
- 208000031968 Cadaver Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000004367 Tibial Fractures Diseases 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000003423 ankle Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000010072 bone remodeling Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000007596 consolidation process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000001599 osteoclastic effect Effects 0.000 description 2
- 230000001009 osteoporotic effect Effects 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 230000000541 pulsatile effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000010907 stover Substances 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000008467 tissue growth Effects 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 231100000759 toxicological effect Toxicity 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 238000011870 unpaired t-test Methods 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010020584 Hypercalcaemia of malignancy Diseases 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000037848 Metastatic bone disease Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000002565 Open Fractures Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 206010034156 Pathological fracture Diseases 0.000 description 1
- 206010034701 Peroneal nerve palsy Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 1
- 208000005250 Spontaneous Fractures Diseases 0.000 description 1
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 238000011882 arthroplasty Methods 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical class [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229940009626 etidronate Drugs 0.000 description 1
- GWBBVOVXJZATQQ-UHFFFAOYSA-L etidronate disodium Chemical compound [Na+].[Na+].OP(=O)([O-])C(O)(C)P(O)([O-])=O GWBBVOVXJZATQQ-UHFFFAOYSA-L 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000011540 hip replacement Methods 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 210000002758 humerus Anatomy 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 229940015872 ibandronate Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000000173 nephrocalcinosis Diseases 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000010258 osteoblastogenesis Effects 0.000 description 1
- 201000010459 osteogenesis imperfecta type 3 Diseases 0.000 description 1
- 230000002138 osteoinductive effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 201000011197 peroneal nerve paralysis Diseases 0.000 description 1
- 238000013001 point bending Methods 0.000 description 1
- 238000011240 pooled analysis Methods 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229940089617 risedronate Drugs 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940019375 tiludronate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPQ2325A AUPQ232599A0 (en) | 1999-08-19 | 1999-08-19 | Drug for treating fractures |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200202160B true ZA200202160B (en) | 2003-08-27 |
Family
ID=3816500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200202160A ZA200202160B (en) | 1999-08-19 | 2002-03-15 | Drug for treating fractures. |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1214079A4 (sk) |
| JP (1) | JP2003507426A (sk) |
| KR (1) | KR20020027562A (sk) |
| CN (1) | CN100345548C (sk) |
| AU (1) | AUPQ232599A0 (sk) |
| BR (1) | BR0013416A (sk) |
| CA (1) | CA2381302A1 (sk) |
| HK (1) | HK1048441B (sk) |
| HU (1) | HUP0202396A3 (sk) |
| IL (1) | IL148166A0 (sk) |
| NO (1) | NO20020784L (sk) |
| NZ (1) | NZ517538A (sk) |
| PL (1) | PL353485A1 (sk) |
| SK (1) | SK2382002A3 (sk) |
| WO (1) | WO2001013922A1 (sk) |
| ZA (1) | ZA200202160B (sk) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0116862A (pt) | 2001-02-06 | 2004-01-13 | Royal Alexandra Hosp Children | Medicamento, métodos para tratar um paciente com osteonecrose e/ou osteocondrite dissecans, para prevenir a osteonecrose e/ou osteocondrite dissecans em um paciente em risco de cada uma das ditas doenças, uso de um medicamento, e, método para prevenir a destruição da cartilagem ou condrólise associadas com osteonecrose e/ou osteocondrite dissecans |
| WO2002080933A1 (en) * | 2001-04-03 | 2002-10-17 | The Royal Alexandra Hospital For Children | A drug for use in bone grafting |
| AUPR553701A0 (en) * | 2001-06-07 | 2001-07-12 | Royal Alexandra Hospital For Children, The | A device for the delivery of a drug to a fractured bone |
| ES2561463T3 (es) * | 2003-08-21 | 2016-02-26 | Addbio Ab | Dispositivo de implante recubierto con bisfosfonato y método para el mismo |
| NZ545804A (en) * | 2003-09-19 | 2009-09-25 | Wisconsin Alumni Res Found | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-or-vitamin D derivatives and a bisphosphonate |
| ITMI20040218A1 (it) * | 2004-02-10 | 2004-05-10 | Abiogen Pharma Spa | Uso di neridronato sodico per promuovere la neoformazione ossea |
| ITMI20040641A1 (it) * | 2004-03-31 | 2004-06-30 | Tb Technology S R L | Composizioni bioadesive bifunzionali per implantologia orale |
| AR048742A1 (es) * | 2004-12-22 | 2006-05-24 | Gador Sa | Sistema de aplicacion de medicamentos intra-oral |
| US8940320B2 (en) | 2005-10-27 | 2015-01-27 | Thommen Medical Ag | Dental implant and production method for said implant |
| US8882740B2 (en) | 2009-12-23 | 2014-11-11 | Stryker Trauma Gmbh | Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone |
| CN114532937A (zh) * | 2020-11-18 | 2022-05-27 | 中国人民解放军海军军医大学第一附属医院 | 一种小肠镜辅助装置 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR8107560A (pt) * | 1981-11-19 | 1983-07-05 | Luiz Romariz Duarte | Estimulacao ultra-sonica da consolidacao de fraturas osseas |
| JPH07502507A (ja) * | 1991-12-17 | 1995-03-16 | プロクター、エンド、ギャンブル、ファーマスーティカルズ、インコーポレーテッド | ビスホスホネート類及び副甲状腺ホルモンを用いた骨粗鬆症の治療方法 |
| AU670337B2 (en) * | 1992-11-30 | 1996-07-11 | Novartis Ag | Use of certain methanebisphosphonic acid derivatives in fracture healing |
| EP0600834A1 (en) * | 1992-11-30 | 1994-06-08 | Ciba-Geigy Ag | Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing |
| EP0675723A4 (en) * | 1992-12-23 | 1998-08-05 | Merck & Co Inc | BIPHOSPHONATE / ESTROGEN THERAPY FOR TREATING AND PREVENTING BONE LOSS. |
| US5403829A (en) * | 1993-03-24 | 1995-04-04 | Leiras Oy | Use of bisphosphonates in endo-osteal bone surgery |
| US5646134A (en) * | 1994-04-21 | 1997-07-08 | Merck & Co., Inc. | Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices |
| GB9408775D0 (en) * | 1994-05-04 | 1994-06-22 | Ciba Geigy Ag | Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration |
| CA2221416A1 (en) * | 1995-06-06 | 1996-12-12 | Merck & Co., Inc. | Bisphosphonate therapy for bone loss associated with rheumatoid arthritis |
| US5616571A (en) * | 1995-06-06 | 1997-04-01 | Merck & Co., Inc. | Bisphosphonates prevent bone loss associated with immunosuppressive therapy |
| US5853759A (en) * | 1996-05-17 | 1998-12-29 | Merck & Co.. Inc. | Effervescent alendronate formulation |
| GB9613722D0 (en) * | 1996-06-28 | 1996-08-28 | Univ Liverpool | Chemical compounds |
-
1999
- 1999-08-19 AU AUPQ2325A patent/AUPQ232599A0/en not_active Abandoned
-
2000
- 2000-08-17 HU HU0202396A patent/HUP0202396A3/hu unknown
- 2000-08-17 CN CNB008117659A patent/CN100345548C/zh not_active Expired - Fee Related
- 2000-08-17 IL IL14816600A patent/IL148166A0/xx unknown
- 2000-08-17 KR KR1020027002160A patent/KR20020027562A/ko not_active Application Discontinuation
- 2000-08-17 JP JP2001518059A patent/JP2003507426A/ja active Pending
- 2000-08-17 WO PCT/AU2000/000982 patent/WO2001013922A1/en active IP Right Grant
- 2000-08-17 CA CA002381302A patent/CA2381302A1/en not_active Abandoned
- 2000-08-17 PL PL00353485A patent/PL353485A1/xx not_active Application Discontinuation
- 2000-08-17 EP EP00952791A patent/EP1214079A4/en not_active Withdrawn
- 2000-08-17 SK SK238-2002A patent/SK2382002A3/sk not_active Application Discontinuation
- 2000-08-17 BR BR0013416-3A patent/BR0013416A/pt not_active Application Discontinuation
- 2000-08-17 NZ NZ517538A patent/NZ517538A/en unknown
-
2002
- 2002-02-18 NO NO20020784A patent/NO20020784L/no not_active Application Discontinuation
- 2002-03-15 ZA ZA200202160A patent/ZA200202160B/en unknown
-
2003
- 2003-01-21 HK HK03100502.8A patent/HK1048441B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20020784D0 (no) | 2002-02-18 |
| PL353485A1 (en) | 2003-11-17 |
| HK1048441B (zh) | 2008-02-22 |
| BR0013416A (pt) | 2002-04-30 |
| HK1048441A1 (en) | 2003-04-04 |
| AUPQ232599A0 (en) | 1999-09-09 |
| JP2003507426A (ja) | 2003-02-25 |
| NO20020784L (no) | 2002-02-18 |
| HUP0202396A2 (hu) | 2002-11-28 |
| CN100345548C (zh) | 2007-10-31 |
| CA2381302A1 (en) | 2001-03-01 |
| WO2001013922A1 (en) | 2001-03-01 |
| EP1214079A4 (en) | 2004-03-24 |
| EP1214079A1 (en) | 2002-06-19 |
| CN1370071A (zh) | 2002-09-18 |
| HUP0202396A3 (en) | 2005-02-28 |
| NZ517538A (en) | 2003-07-25 |
| KR20020027562A (ko) | 2002-04-13 |
| SK2382002A3 (en) | 2002-09-10 |
| IL148166A0 (en) | 2002-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yıldız et al. | Effect of zoledronic acid on osseointegration of titanium implants: an experimental study in an ovariectomized rabbit model | |
| WO2002098307A1 (en) | A device for the delivery of a drug to a fractured bone | |
| Little et al. | Intravenous pamidronate reduces osteoporosis and improves formation of the regenerate during distraction osteogenesis: A study in immature rabbits | |
| Tudor et al. | Static and dynamic periosteal elevation: a pilot study in a pig model | |
| Pampu et al. | Experimental evaluation of the effects of zoledronic acid on regenerate bone formation and osteoporosis in mandibular distraction osteogenesis | |
| ZA200202160B (en) | Drug for treating fractures. | |
| NO310057B1 (no) | Anvendelse av visse metanbisfosfonsyrederivater for å forhindre lösning av protese og protesemigrering | |
| Küçük et al. | Comparison of local and systemic alendronate on distraction osteogenesis | |
| Little et al. | Effect of pamidronate on distraction osteogenesis and fixator-related osteoporosis | |
| AU5973496A (en) | Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices | |
| Oteo-Álvaro et al. | Teriparatide (rh [1–34] PTH) improved osteointegration of a hemiarthroplasty with signs of aseptic loosening | |
| EP2953632A1 (en) | Amorphous calcium carbonate for accelerated bone growth | |
| Linderbäck et al. | Weak effect of strontium on early implant fixation in rat tibia | |
| Harding et al. | A single dose zoledronic acid enhances pin fixation in high tibial osteotomy using the hemicallotasis technique. A double-blind placebo controlled randomized study in 46 patients | |
| Tarvainen et al. | Effect of clodronate on fracture healing in denervated rats | |
| Gasser et al. | A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats | |
| AU781068B2 (en) | Drug for treating fractures | |
| CA2353528C (en) | Use of ibandronate for promoting osseointegration of endoprostheses | |
| Kurth et al. | Ibandronate treatment decreases the effects of tumor-associated lesions on bone density and strength in the rat | |
| Goodship et al. | Prevention of strain‐related osteopenia in aseptic loosening of hip prostheses using perioperative bisphosphonate | |
| Alshahrani et al. | Ranitidine impairs bone healing and implant osseointegration in rats' tibiae | |
| Kakar et al. | Can we improve fixation and outcomes in the treatment of femoral neck fractures? The use of pharmaceuticals | |
| JP2010526064A (ja) | 骨組織の成長の育成および保存のための方法および組成物 | |
| Saghieh et al. | The impact of zoledronic acid on regenerate and native bone after consolidation and removal of the external fixator: an animal model study | |
| KR102451667B1 (ko) | 골, 연골, 치아 및 치주의 재생 및 종양 및 낭포의 치료를 위한 제형 |